Assura Group Limited
18 September 2007
18 September 2007
Enquiries: Richard Burrell/Nigel Rawlings/Louise Bathersby Tel: 020 7107 3800
Assura Group
Tony Langham/Henrietta Guthrie/Charlotte Edgar Tel: 07979 692 287 / 020 7294
Lansons Communications 3612 / 020 7294 3622
Assura Group Limited (the 'Company' or 'Group')
Unaudited Interim Results to 30 June 2007
Assura Group works in partnership with GPs and Health Professionals to deliver
property, pharmacy and medical services in primary care.
These unaudited interim results are in respect of the six month period to 30
June 2007.
Highlights:
• Group operating profit £8.3m (2006: £7.2m)
• Interim dividend up 17% to 2.33p(1) (2006: 2.00p)
• Net assets up 7% to £286.5m equivalent to 123.2p per Share compared to
114.3p at 31 December 2006.
• Eight joint ventures with GPs formed to provide out-patient and diagnostic
procedures to a population of circa 1m patients
• 15 (2006: 4) pharmacies open(2) - EBITDA positive at branch level this year
• Invested or committed £493m (2006: £385m) across 135 sites of which 21 are
currently in solicitors' hands(2)
• On track to have joint ventures providing services to 1.5m patients and 20
pharmacies by end 2007 and to invest or commit £600m on property by 31
March 2008
(1) Ex-dividend date 26 September 2007, record date 28 September 2007, payment
date 19 October 2007.
(2) As at 01 September 2007.
Commenting on the Results, Richard Burrell, Chief Executive of the Company,
said:
'The Company continues to evolve rapidly into a primary and community care
provider organisation. With our strong asset backing we are able to offer our GP
partners, pharmacists and patients modern integrated facilities which are suited
to the evolving NHS and are capable of undertaking many services which have
hitherto been carried out in hospitals.
'The medical division has formed eight joint ventures serving circa 1m patients
and is on track to have over 1.5m patients by the end of this financial year.
Out-patient services have commenced in Liverpool, Bath and Macclesfield and
there are many other services being bid for or planned. The pharmacy division
has 15 pharmacies trading with a further five scheduled to open in the next
three months. Next year we intend to open or invest in another 20 pharmacies
taking the total, by 31 March 2009, to a minimum of 40 pharmacies. The property
division is on track to have £600m invested or committed by 31 March 2008 and
£750m by end 2009.
'We believe that by having a modern portfolio of property assets capable of
housing GPs and other health providers, locating our own pharmacies within these
facilities and by entering into collaborative joint ventures with GPs to provide
out-patient and related services as a 'willing provider'(i) we will build a
strong and effective group capable of becoming one of the leading providers of
NHS services to patients.'
The full text of the Interim Results are available on RNS.
Ends
--------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.